Macquarie Group LTD Viridian Therapeutics, Inc.\De Transaction History
Macquarie Group LTD
- $86.4 Billion
- Q4 2024
A detailed history of Macquarie Group LTD transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Macquarie Group LTD holds 142,393 shares of VRDN stock, worth $2.27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142,393
Previous 143,395
0.7%
Holding current value
$2.27 Million
Previous $3.26 Million
16.34%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$76 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$73.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$72 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$61.8 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$56.1 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $635M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...